Fighting infections due to multidrug-resistant Gram-positive pathogens

Area of Science:

• Microbiology
• Infectious Diseases
• Pharmacology

Background:

• Growing bacterial resistance in Gram-positive pathogens compromises existing treatments like penicillin and macrolides.
• Multidrug-resistant (MDR) Gram-positive pathogens present an urgent and often unmanageable clinical problem.
• The precise human health risks of antibiotic resistance remain poorly defined due to data limitations and methodological issues.

Discussion:

• Effectiveness of interventions to control antibiotic resistance is not well understood.
• New antibiotics targeting MDR Gram-positive pathogens are emerging, with more in development.
• Novel agents may be niche, necessitating a shift in attitudes towards broad-spectrum antibiotics.

Key Insights:

• Antibiotic resistance in Gram-positive bacteria is rendering common treatments ineffective.
• There is a critical need for better data on the clinical outcomes of antibiotic resistance.
• Current knowledge on the efficacy of resistance control strategies is limited.

Outlook:

• The pipeline includes new glycopeptides, anti-MRSA beta-lactams, and diaminopyrimidines.
• Future antibiotics may have narrow spectra, requiring educational shifts among prescribers and patients.
• Professional societies like ESCMID are crucial for guiding the response to antibiotic resistance.